OnKure director granted 7,650 stock options
OnKure Therapeutics director Michael G. Grey received a grant of 7,650 stock options to purchase Class A common stock at an exercise price of $4.30 per share.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
OnKure Therapeutics director Michael G. Grey received a grant of 7,650 stock options to purchase Class A common stock at an exercise price of $4.30 per share. These options vest 100% on the earlier of June 4, 2027 or the day before the company’s next annual stockholder meeting, provided he continues as a service provider, and expire on June 3, 2036.
Insider Trade Summary
Grant/Award: 7,650 shares
Grant/Award
1 txn
Insider
GREY MICHAEL G
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 7,650 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 7,650 contracts (Direct)
Footnotes (1)
- F1. 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date.
Key Figures
Options granted: 7,650 options
Exercise price: $4.30 per share
Total options after grant: 7,650 options
+2 more
5 metrics
Options granted
7,650 options
Stock Option (right to buy) grant on June 4, 2026
Exercise price
$4.30 per share
Conversion or exercise price for Class A Common Stock
Total options after grant
7,650 options
Derivative securities beneficially owned following transaction
Option expiration
June 3, 2036
Expiration date of the stock option grant
Vesting date trigger
June 4, 2027 or earlier meeting date
100% vesting on earlier of June 4, 2027 or day before next annual meeting
Key Terms
Stock Option (right to buy), exercise price, vesting, Class A Common Stock, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: "Stock Option (right to buy)""
exercise price financial
"conversion_or_exercise_price: "4.3000""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"100% of the shares subject to the option will vest on the earlier of June 4, 2027"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Class A Common Stock financial
"underlying_security_title: "Class A Common Stock""
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
derivative securities financial
"derivativeTransactionCount: 1"
Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did OnKure Therapeutics (OKUR) director Michael G. Grey report on this Form 4?
Michael G. Grey reported receiving a grant of 7,650 stock options for OnKure Therapeutics Class A common stock. The filing shows this as a compensation-related acquisition, not an open-market purchase or sale, and reflects his total derivative holdings after the grant.
What are the key terms of Michael G. Grey’s OnKure (OKUR) stock option grant?
The grant covers 7,650 stock options with an exercise price of $4.30 per share. All options relate to Class A common stock and expire on June 3, 2036, giving the director the right to buy shares at that set price until expiration.
When do Michael G. Grey’s OnKure (OKUR) options vest according to the Form 4?
The options vest 100% on the earlier of June 4, 2027 or the day prior to OnKure’s next annual stockholder meeting. Vesting is conditioned on Grey continuing to serve as a service provider through the applicable vesting date, as described in the footnote.
How many OnKure (OKUR) options does Michael G. Grey hold after this transaction?
After this reported transaction, Grey holds 7,650 stock options directly, according to the Form 4. The filing lists this number as the total derivative securities beneficially owned following the grant, all tied to OnKure Class A common stock.
AI-generated analysis. How Rhea-AI works. Not financial advice.
